Silvan Tuerkcan
Stock Analyst at JMP Securities
(3.12)
# 1,283
Out of 4,496 analysts
112
Total ratings
40%
Success rate
2.69%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Market Outperform | $24 → $21 | $8.60 | +144.19% | 8 | Jul 18, 2024 | |
| ELEV Elevation Oncology | Reiterates: Market Outperform | $7 | $2.64 | +165.15% | 4 | Jul 15, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Market Outperform | $5 | $2.14 | +133.64% | 10 | Jun 20, 2024 | |
| CLLS Cellectis | Reiterates: Market Outperform | $6 | $2.03 | +195.57% | 6 | May 31, 2024 | |
| VOR Vor Biopharma | Reiterates: Market Outperform | $12 | $0.92 | +1,199.69% | 9 | May 13, 2024 | |
| MGNX MacroGenics | Maintains: Market Outperform | $22 → $16 | $4.92 | +225.20% | 10 | May 10, 2024 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $54.56 | +57.62% | 11 | May 9, 2024 | |
| TERN Terns Pharmaceuticals | Reiterates: Market Outperform | $15 | $8.49 | +76.78% | 8 | Apr 30, 2024 | |
| ACRV Acrivon Therapeutics | Maintains: Market Outperform | $14 → $17 | $7.33 | +131.92% | 3 | Apr 25, 2024 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $10 → $16 | $9.22 | +73.54% | 7 | Apr 22, 2024 | |
| NTBL Notable Labs | Reiterates: Market Outperform | $9 | $0.72 | +1,150.00% | 3 | Apr 15, 2024 | |
| EXEL Exelixis | Reiterates: Market Outperform | $27 | $22.60 | +19.47% | 11 | Apr 10, 2024 | |
| MNDY monday.com | Maintains: Buy | $240 → $280 | $228.65 | +22.46% | 3 | Mar 5, 2024 | |
| GBIO Generation Bio Co. | Downgrades: Market Perform | n/a | $2.88 | - | 7 | Oct 23, 2023 | |
| TWO Two Harbors Investment | Maintains: Market Outperform | $18 → $18 | $13.68 | +31.58% | 1 | Jan 26, 2023 | |
| NTLA Intellia Therapeutics | Downgrades: Market Perform | n/a | $25.08 | - | 8 | Jan 19, 2023 | |
| LOGC ContextLogic | Maintains: Market Outperform | $2 → $3 | $6.00 | -50.00% | 3 | May 10, 2022 |
Relay Therapeutics
Jul 18, 2024
Maintains: Market Outperform
Price Target: $24 → $21
Current: $8.60
Upside: +144.19%
Elevation Oncology
Jul 15, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $2.64
Upside: +165.15%
Taysha Gene Therapies
Jun 20, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $2.14
Upside: +133.64%
Cellectis
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $2.03
Upside: +195.57%
Vor Biopharma
May 13, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $0.92
Upside: +1,199.69%
MacroGenics
May 10, 2024
Maintains: Market Outperform
Price Target: $22 → $16
Current: $4.92
Upside: +225.20%
CRISPR Therapeutics AG
May 9, 2024
Reiterates: Market Outperform
Price Target: $86
Current: $54.56
Upside: +57.62%
Terns Pharmaceuticals
Apr 30, 2024
Reiterates: Market Outperform
Price Target: $15
Current: $8.49
Upside: +76.78%
Acrivon Therapeutics
Apr 25, 2024
Maintains: Market Outperform
Price Target: $14 → $17
Current: $7.33
Upside: +131.92%
Benitec Biopharma
Apr 22, 2024
Maintains: Market Outperform
Price Target: $10 → $16
Current: $9.22
Upside: +73.54%
Notable Labs
Apr 15, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $0.72
Upside: +1,150.00%
Exelixis
Apr 10, 2024
Reiterates: Market Outperform
Price Target: $27
Current: $22.60
Upside: +19.47%
monday.com
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $228.65
Upside: +22.46%
Generation Bio Co.
Oct 23, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.88
Upside: -
Two Harbors Investment
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $13.68
Upside: +31.58%
Intellia Therapeutics
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $25.08
Upside: -
ContextLogic
May 10, 2022
Maintains: Market Outperform
Price Target: $2 → $3
Current: $6.00
Upside: -50.00%